Pathological accumulation of tau and amyloid in the brains of Alzheimer’s disease (AD) patients leads to a continuum of irreversible biochemical and pathological changes and pronounced neurodegeneration. Impaired ‘glymphatic’ clearance may be one of the earliest biological changes in AD, occurring many years prior to neurodegeneration, and therefore presents a unique opportunity for strategic therapeutic intervention. Here, we have mapped the extent of glymphatic inflow of an MRI contrast agent from cerebrospinal fluid, into the brain parenchyma. Leading on from previous studies, we have demonstrated that glymphatic inflow is impaired during the onset of pathology in an AD animal model.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords